Pharmaceutical

TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of Approval

TNT-119 is under clinical development by Eliem Therapeutics and currently in Phase I for Membranous Glomerulonephritis.

May 19, 2024 - 04:00
TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of Approval
TNT-119 is under clinical development by Eliem Therapeutics and currently in Phase I for Membranous Glomerulonephritis.
Read the original article

Tags:

Previous Article

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of ...

Next Article

IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: AI can speed up drug discovery but don’t expect it to cure cancer, yet

STAT+: AI can speed up drug discovery but don’t expect ...

Feb 7, 2024

The Witty Answer to GSK’s Future

The Witty Answer to GSK’s Future

Apr 16, 2023

MBX-1416 by MBX Biosciences Inc for Hypoglycemia: Likel...

Nov 4, 2023